BREAKTHROUGH COGNITIVE SCREENING TECHNOLOGY WITH CMS BILLING CODES
- Cutting Edge Technology with no industry equivalent
- Projected EBITDA of $16M by 2024 & by $467M by 2028
- 4 large Market Segments with several niches in each
- FDA Registered
- 5 Revenue Streams with detailed revenue strategies
- Approved CMS Reimbursements Codes with rates from $435-$570
- Estimated 61.2M Medicare covered patients
- Clinical trials resulted in Contracts with US Army and Veteran’s Administration
- 5 Product Offerings with patents, trademarks & copyrights
- Proprietary Software analyzes data in real time
- Configured Web Portal for reporting & insurance billing
- Healthcare Providers profitable with first patient screening
- Low Production Costs estimated at 7.4% of revenue by 2024
- Population of Potential Markets 1.085 Billion
A unique opportunity for a strategic buyer to acquire cutting edge technology unparalleled in the industry.
Vast markets in Medical, Defense, Education and Sports relating to Dementia, Alzheimer’s, Parkinson’s, Strokes, Concussions, Learning Disabilities, Cognitive Impairments, and others.
This patented, innovative medical breakthrough has the potential to completely change the landscape of cognitive screening and treatment. The systems and technology are FDA registered with their own CMS billing codes.
The ownership now feels their devices and technology is fully developed, which brings them to a juncture where they would consider a divestiture with a company capable of capitalizing on the opportunity to propel this technology more quickly to a waiting global market.
It has taken 22 years of R&D to commercialize this product line, and the proven clinical trials and having accomplished CMS billing codes, makes this offering an extraordinary opportunity for investment in the next generation of cognitive screening and treatment.